CAS: 146000-39-7; Boc-N-Me-Aib-Oh

相似化合物

15030-72-5 30992-29-1 94744-50-0

上下游产品

CAS号30992-29-1 N-叔丁氧羰基-2-甲基丙氨酸 | CAS号74-88-4 碘甲烷 | CAS号2566-34-9 N,2-二甲基-丙氨酸 | CAS号24424-99-5 二碳酸二叔丁酯 | CAS号220022-94-6 2-(二甲基氨基)-2-甲基丙酸

📜2-((叔丁氧羰基)氨基)-2-甲基丙酸甲酯置于水,Sodium Hydride,Lithium Hydroxide体系中,用 1,4-二氧六环,N,N-二甲基甲酰胺,Mineral Oil 用作溶剂,化学反应 45.5H,反应生成N-Boc-N,2-二甲基丙氨酸
参考文献:苯并氮杂-杂的异二氢吲哚通过三甲亚胺叶立德与二硝基芳烃的分子内(3 + 2)-环加成反应
标题:苯并氮杂-杂的异二氢吲哚通过三甲亚胺叶立德与二硝基芳烃的分子内(3 + 2)-环加成反应
摘要:带有3,5-二硝基苯基侧基的氨基苯甲醛与n-取代的α-氨基酸发生热反应,形成前所未有的苯并氮杂稠合的异二氢吲哚.反应通过脱芳香化/再芳香化顺序进行,该顺序涉及原位形成的甲亚胺基立德和二硝基芳烃之间的分子内(3 + 2)-环加成.基于环状,α-单-和α,α-二取代的氨基酸,可以耐受各种甘氨酸衍生物以及支链的底物,在许多情况下可得到单一的非对映异构体.该方法是可扩展的,并提供具有硝基基团的产品以备进一步处理.
Doi:10.1021/acs.Orglett.9B01580

专利信息

专利号:US-6992097-B2
优先权日:1998-08-18
标 题 :Growth hormone secretagogues
发明人：HAUSER KENNETH LEE; DODGE JEFFREY ALAN; HEIMAN MARK LOUIS; JONES SCOTT ALAN; ALT CHARLES ARTHUR; BRYANT HENRY UHLMAN; COHEN JEFFREY DANIEL; COPP JAMES DENSMORE; FAHEY KENNAN JOSEPH; GRITTON WILLIAM HARLAN; JUNGHEIM LOUIS NICKOLAUS; KENNEDY JOSEPH HENRY; LUGAR III CHARLES WILLIS; MUEHL BRIAN STEPHEN; PALKOWITZ ALAN DAVID; RATZ ANDREW MICHAEL; RHODES GARY ANTHONY; ROBEY ROGER LEWIS; SEYLER DAVID EDWARD; SHEPHERD TIMOTHY ALAN; THRASHER KENNETH JEFF; TRANKLE WILLIAM GEORGE
权利人:LILLY CO ELI
摘要:This invention relates to novel compounds which are useful in the modulation of endogenous growth hormone levels in a mammal. The invention further relates to novel intermediates for use in the synthesis of said compounds, as well as novel processes employed in these syntheses. Also included are methods of treating a mammal which include the administration of said compounds.

专利号:US-7989438-B2
优先权日:2007-07-17
标题 :Therapeutic compounds
发明人：CONTE IMMACOLATA; HABERMANN JOERG; MACKAY ANGELA; NARJES FRANK; RICO FERREIRA MARIA DEL ROSARIO; STANSFIELD IAN
权利人:ANGELETTI P IST RICHERCHE BIO
摘要:A class of macrocyclic compounds of formula (I), wherein R 7 , A, Ar, B, D, F, M, Q 1 , Q 2 , W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.